STMN2 and amyotrophic lateral sclerosis: Nevertheless, these and other transcript‐level alterations warrant further investigation as candidate biomarkers, as supported by the recent reports of STMN2 [49] and UNC13A [50, 51] in ALS post‐mortem tissue and the alternative splicing events seen in the peripheral blood of other neurological disorders [52, 53].